FDA Approves New Treatment for Moderate-to-Severe Eczema

April 6, 2017

FDA approves injection totr eat Severe Eczemain in Adults

On Tuesday, March 28th, the FDA announced the approval of Dupixent (dupilumab), an injection for the treatment of adults with moderate-to-severe atopic dermatitis.

What is Atopic Dermatitis?

Atopic dermatitis is a chronic inflammatory skin disease that “is often referred to as ‘eczema,’ which is a general term for several types of inflammation of the skin.” Atopic dermatitis is the most common form of eczema.  It is most prevalent in children, but can last through adulthood and can occur at any age. The condition is caused by a combination of genetic, immune, and environmental factors, and affects the skin’s ability to hold moisture.

Symptoms of Eczema

“In atopic dermatitis, the skin develops red, scaly and crusted bumps, which are extremely itchy. Scratching leads to swelling, cracking, “weeping” clear fluid, and finally, coarsening and thickening of the skin,” states a recent press release from the FDA.  Additionally, people who suffer from eczema are more also likely to develop asthma and/or seasonal allergies.

Treating Eczema

From simple lotions to steroid creams and immune suppressant drugs, there are a variety of products on the market that are used to treat eczema.  However, none of these treatments work for everyone suffering from the condition, “and the immune suppressant drugs can raise the risk of cancers such as lymphoma,” claims a recent article from NBC News.  As such, eczema and its treatment has been an ongoing struggle for many suffering from the uncomfortable condition.

FDA-Approval of Dupixent

Last month the Agency approved Dupixent, providing patients with a solution to the ongoing battle with the unpleasant skin condition.  Dupixent is manufactured by Regeneron Pharmaceuticals, Inc., and was approved via the FDA’s Priority Review and Breakthrough Therapy designation.

Dupixent is administered twice-a-month as an injection under the skin.  The product can be used with or without topical corticosteroids, and is intended for serious cases of eczema in which topical therapies have not helped, or situations where topical therapies are not advisable.

The injection’s “active ingredient is an antibody (dupilumab) that binds to a protein [interleukin-4 (IL-4) receptor alpha subunit (IL-4Ra)], that causes inflammation. By binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis.”

Safety & Efficacy of Dupixent

Regeneron established the safety and efficacy of Dupixent in three placebo-controlled clinical trials, in which there were 2,119 adult participants suffering from moderate-to-severe atopic dermatitis that was not being adequately controlled by topical medication(s).  “Overall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.”

Although many patients with eczema also suffer from allergies and asthma, the FDA draws attention to the fact that the product has not been approved for the treatment of asthma.  As such, the Agency states that individuals should not adjust or stop their asthma treatment without speaking to their physician.

Side Effects of Dupixent

The most common side effects associated with the use of Dupixent include:

  • Injection site reactions
  • Cold sores in the mouth or on the lips
  • Eye and eyelid inflammation (redness, swelling, and itching)

Some more serious side effects can include serious allergic reactions and eye problems, including pink eye (conjunctivitis) and inflammation of the cornea (keratitis).  Patients are advised to contact their health care provider if they “experience new or worsening eye symptoms such as redness, itching, pain or visual changes.”

FDA’s Commitment to Approving New & Innovative Therapies

In the Agency’s press release, Julie Beitz, MD, Director of the Office of Drug Evaluation III, stated that this approval demonstrates the FDA’s “commitment to approving new and innovative therapies for patients with skin disease.  Eczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies.”

The approval of a new treatment for eczema will fill a huge unmet need that will help thousands of people suffering from the skin condition.  However, there are still a plethora of conditions without any known or approved treatments.  In an effort to get new and innovative therapies on the market, FDA may expedite the approval process for products that are indicated for these conditions.  Developing these products is a very challenging task, and getting them approved by the Agency can be just a difficult.  That is why we are here to help.

We have a proven track-record of helping our clients achieve successful interactions with the FDA.  If you are in the process of developing or seeking approval of an FDA-regulated product, we can help.  Contact us today to learn more about our capabilities and to find out how we can help get your product through the FDA and on the market.


April 4, 2016

FDA Modifies Certain Medical Device Requirements

On Monday, April 4th, FDA announced a publication entitled “Modifications to the List of Recognized Standards, Recognition List Number: 041,” which contains modifications to the list of standards FDA...

May 16, 2017

FDA Approves New Drug to Treat ALS

Anyone who was on social media in the summer of 2014 knows what the Ice Bucket Challenge was. Videos of people completing the challenge littered most people’s social media feeds, all in hopes of...

March 24, 2017

510(k) Database Enables Sponsors to Search for Substantially Equivalent Medical Devices

Sponsors no longer have to rely on checking lists of 510(k) devices when looking to make a substantial equivalence claim. While the FDA does release an updated list each month, Sponsors can save time...